SERENDIP INNOVATIONS

What this means for you

Not registered yet, but its 15 Nov 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

79414532

Mark type

Stylized text

Filed

15 Nov 2024

Attorney of record

Cathleen E. Stadecker

Goods and services

• Class 005 — Pharmaceuticals: Medicines for human medicine designed based on the enhanced VLP (virus-like particle) technology; Anti-cancer medicines; Immunosuppressive medicines; Immunomodulator medicines for treating autoimmune diseases, cancer, infections; Anti-inflammatory medications; Tonics being medicines designed based on the enhanced VLP (virus-like particle) technology; Vaccines; Vaccines for human use; Vaccines for the treatment of cancer; Cellular function activating agents for medical purposes; Biopharmaceutical products for cancer treatment; Pharmaceutical preparations for use in oncology for cancer treatment; Pharmaceuticals for the treatment of inflammatory diseases, namely, anti- inflammatories; Biological preparations for the treatment of cancer; Immunotherapeutic agents for bacterial infections; Immune modulators being pharmaceutical preparations for the treatment of immune system related diseases and disorders; Immunostimulants; Pharmaceuticals for use in the treatment of diseases and disorders in the fields of oncology, immunology, intensive therapeutic assets medicine, and organ transplantation medicine; Pharmaceuticals for influencing the immune system for treatment of autoimmune diseases, cancer, infections; Pharmaceuticals for the prevention and treatment of viral diseases, namely, vaccines against infectious diseases and viral infections; Pharmaceuticals for the treatment of diseases of the immune system; Pharmaceuticals for the treatment of oncological diseases; Biological preparations for medical use for treating autoimmune diseases, cancer, infections; Mixed biological preparations for medical use for treating autoimmune diseases, cancer, infections; Biochemical preparations for medical use for treating autoimmune diseases, cancer, infections; Chemical-pharmaceutical preparations for treating autoimmune diseases, cancer, infections; chemical preparations for medical use for treating autoimmune diseases, cancer, infections; Phytotherapy preparations for medical use; Diagnostic preparations for medical use; Medical and pharmaceutical substances and preparations used in oncology; Medical and pharmaceutical substances and preparations used in immunology; Reagents for medical use; Chemical reagents for medical use; Diagnostic biomarking reagents for medical use; Anti-inflammatories; Antibiotics
• Class 042 — Scientific and technological services: Research and development services in the field of chemistry, biology and biochemistry; Research and development services in the field of oncology; Research and development services in the field of cancerous diseases; Research and development services in the field of immunology; Research and development services in the field of vaccinology; Research and development services in the field of bacteriology and virology; Research and development services in the field of antibody technology; Research and development in the field of antibodies; Research and development services in the field of animal health; Technical project study services being scientific research services in the field of chemistry, biology and biochemistry; Technical project study services being scientific research services in oncology, immunology and vaccinology; Biological research; Research in bacteriology and virology; Technical project study services being scientific research services in the field of animal health; Research in chemistry, biology and biochemistry; Research in oncology, immunology and vaccinology; Scientific research conducted using databases; Scientific research for medical purposes in the field of oncology; Scientific research for medical purposes in the field of cancerous diseases; Scientific research for medical purposes in the field of immunology; Scientific research for medical purposes in the field of vaccinology; Scientific research for medical purposes in the field of virology and bacteriology; Technical research in the field of therapeutic candidates design, screening, development, production and quality control testing; Chemical, biological and biochemical technology research; Technical writing; Chemistry, biology and biochemistry services, namely, design, screening, development, production and quality control testing of therapeutic candidates; Scientific laboratory services; Scientific research services; Scientific research services for medical purposes; Research laboratory services; Research and development in the field of biotechnology; Research and development in the field of oncology, immunology and vaccinology; Scientific testing of drug substances and drug products; Scientific research in the nature of carrying out clinical trials for others; Scientific services, namely, design, screening, development, production and quality control testing of therapeutic candidates; Scientific design services, namely, therapeutic candidates design and production processes; Advisory services relating to research and development in the field of therapeutics; Medicine discovery services; Development of pharmaceutical preparations and medicines; Developing gene-based, antigen-based medicines; Research and development of vaccines and medicines; Research and development services with respect to vaccines; Research and development of medicines; Research and development of siRNA-based medicines; Providing medical and scientific research information in the field of clinical trials, namely, provision of medical and scientific research information concerning the results of clinical trials for pharmaceutical products; Provision of information relating to medical preparations research and development; Research laboratory analysis services in the field of chemistry, biology and biochemistry; Scientific research; Scientific analysis, namely, chemical analysis biological analysis; Conducting of technical project studies being scientific research and development services; Providing scientific research services; Preparing project analysis studies, namely, conducting scientific feasibility studies; Preparation of technical surveys being technical surveying services; Scientific research and development, namely, preparation of reports concerning scientific research; Scientific research and development, namely, preparation of scientific reports; Carrying out technical scientific feasibility studies; Research in the field of bioengineering; Information service concerning scientific research; Scientific information service, namely, providing scientific information in the field of design, screening, development, production and quality control testing of therapeutic candidates; Industrial analysis and research services in the field of chemistry, biology and biochemistry; Laboratory testing services for testing of materials; Consultant services in the field of scientific research; Advice relating to scientific research; Scientific research and development advisory services; Human and animal health medicine discovery services; Development of testing methods, namely, development and establishment of testing specifications and procedures for the pharmaceutical industry; Vaccine discovery services

Owner

• Serendip Innovations SAS, FR
• Serendip Innovations SAS, FR

Prosecution history

• 05 Mar 2026 — CHANGE OF NAME/ADDRESS REC'D FROM IB
• 17 Jan 2026 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
• 17 Jan 2026 — LETTER OF SUSPENSION E-MAILED
• 17 Jan 2026 — SUSPENSION LETTER WRITTEN
• 31 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 31 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 31 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 19 Jul 2025 — REFUSAL PROCESSED BY IB
• 01 Jul 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 01 Jul 2025 — REFUSAL PROCESSED BY MPU
• 30 Apr 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
• 29 Apr 2025 — NON-FINAL ACTION WRITTEN
• 23 Apr 2025 — ASSIGNED TO EXAMINER
• 12 Jan 2025 — APPLICATION FILING RECEIPT MAILED
• 12 Jan 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED